Mein Überblick Tagesgewinner - 500 Beiträge pro Seite

[GooGel]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=NVDA&uf=8&type=4&size=4&sid=129254&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=8&rand=1142507834&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

JDSTDirexion Daily Junior Gold Miners Index Bear 3X Shares

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=JDST&uf=8&type=4&size=4&sid=13354696&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=7&rand=1866720158&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

Navios Maritime Holdings Inc

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=NM&uf=8&type=4&size=4&sid=2101474&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=49264430&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

Triton International Ltd

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=TRTN&uf=8&type=4&size=4&sid=23881258&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1101943026&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

AAC Holdings Inc.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=AAC&uf=8&type=4&size=4&sid=15938961&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1836364837&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

ProShares UltraShort Gold Miners

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=GDXS&uf=8&type=4&size=4&sid=18327838&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=976700800&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

Scorpio Bulkers Inc!!!!!!!!!!!!!!!!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=SALT&uf=8&type=4&size=4&sid=13833215&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1044228482&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=SALT&uf=8&type=4&size=4&sid=13833215&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1044228482&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

Scorpio Bulkers Inc. und Eagle Bulk Shipping

http://www.foxbusiness.com/markets/2016/11/11/why-scorpio-bu…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=EGLE&uf=8&type=4&size=4&sid=2017046&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=7&rand=1539934349&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

Textainer Group Holdings Ltd!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=TGH&uf=8&type=4&size=4&sid=2887964&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1219320758&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

MODN Model N Inc.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=MODN&uf=8&type=4&size=4&sid=12204614&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1268232203&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

DHX DHI Group Inc.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=DHX&uf=8&type=4&size=4&sid=2775939&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1573189436&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

ZSL ProShares UltraShort Silver

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=ZSL&uf=8&type=4&size=4&sid=6500503&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=835465141&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

SOXL Direxion Daily Semiconductor Bull 3X Shares

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=SOXL&uf=8&type=4&size=4&sid=4571579&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=13&rand=1936231438&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=SOXL&uf=8&type=4&size=4&sid=4571579&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=13&rand=1936231438&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

LXFT Luxoft Holding Inc.!!!!!!!!!!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=LXFT&uf=8&type=4&size=4&sid=12656577&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=757600594&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

ONDK On Deck Capital Inc.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! REPORT

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=ONDK&uf=8&type=4&size=4&sid=17215765&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1564191347&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

PTCT PTC Therapeutics Inc.!!!!!!!!!!!!!!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=PTCT&uf=8&type=4&size=4&sid=12636551&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1586573682&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

HEAR Turtle Beach Corp.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!KUV 0,3!!!!!!!!!!!Ziel 12 aktuell 1,81

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=HEAR&uf=8&type=4&size=4&sid=5516787&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=93646011&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

HEAR ALL DATE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! die neue AAPL?

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=HEAR&uf=8&type=4&size=4&sid=5516787&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=81004280&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

FATE Fate Therapeutics Inc.!!!!!!!!!!!!!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=FATE&uf=8&type=4&size=4&sid=13198445&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=180465702&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

CGNT Cogentix Medical Inc. noch kleine Umsätze!!!!!!!!!!!! 2 ziel 6 bis 10!!!!!!!!!!!!!!!!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=CGNT&uf=8&type=4&size=4&sid=9646&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1853188644&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

CGNTCogentix Medical Inc. (NASDAQ) DAS IST SIE!!!!!!!!!!!!!!!!!!!!!! 2 Ziel 6-/8/14

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=CGNT&uf=8&type=4&size=4&sid=9646&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=119227164&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

http://www.cogentixmedical.com/ Erst 2 Börsenbriefe!!!!!!!!!!!!Sie werden noch wach!!!!!!!!!!

http://www.cogentixmedical.com/

http://www.duncanindependent.com/penny-stock-news-looking-cl…

http://www.engelwooddaily.com/volume-spiking-and-volatility-…

[GooGel]

CGNT Market KAP $42.47M KUV!!!!!!!!!!! KGV!!!!!!!!!!!!!!!!! Pharma..........Cogentix Medical

http://www.marketwatch.com/story/cogentix-medical-reports-13…

[GooGel]

CGNT ist es 2 Ziel 30 wird kommen!!!!!!!!!!!! Das Ding geht ab!!!!!!!!! die AAPL

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=CGNT&uf=8&type=4&size=4&sid=9646&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=119227164&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]


Infos sammeln..............Ist aber bekannt, das ist gut

[GooGel]

SINO Sino-Global Shipping America Ltd. !!!!!!!!!!!!!!! 1,4 Ziel 8!!!!!!!!!!!!!!!!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=SINO&uf=8&type=4&size=4&sid=3218380&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=2009753381&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

CXRX Concordia International Corp.!!!!!!!!!!! SHORTSQUEZZE!!!!!!!!!!!!!KANDIDAT!!!!!!!!!!!!!!! 2,8 Ziel 16

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=CXRX&uf=8&type=4&size=4&sid=14026218&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=7&rand=701579687&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

VTL Vital Therapies Inc!!!!SHORTSQUEZZE!!!!!! 6 Ziel 12 un 18!!!!!!noch kleine Umsätze

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=VTL&uf=8&type=4&size=4&sid=13758312&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=207954011&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]



noch keine news

umsätze gering


Vital Therapies Inc. (VTL) Moves Higher on Volume Spike for ...
Equities.com-vor 18 Stunden
Vital Therapies Inc. (VTL) traded on unusually high volume on Nov. 11, as the stock gained 23% to close at $6.15. On the day, Vital Therapies ...
Breaking: Will Vital Therapies Inc Short Squeeze Soon?
Frisco Fastball-10.11.2016
Popular Mover to Observe- Vital Therapies, Inc. (NASDAQ:VTL)
Hot Stocks Point-11.11.2016
Price Target Of Vital Therapies, Inc. (NASDAQ:VTL) Stock At $8.5
Enterprise Leader-11.11.2016
Upsurging Stock Gaining Pre-Bell: Vital Therapies, Inc. (NASDAQ:VTL)
AR News-11.11.2016
Alle ansehen
Nachrichtenbild für "Vital Therapies Inc." von The Highbury Clock
The Highbury Clock
Volume Spiking and Volatility in Focus for Vital Therapies, Inc ...
Engelwood Daily-vor 15 Stunden
Shares of Vital Therapies, Inc. (NASDAQ:VTL) are showing high volatlity in today's session as the stock

as moved 23.00%, clocking in at $6.15 ...



http://friscofastball.com/2016/11/10/breaking-will-vital-the…


https://www.equities.com/news/vital-therapies-inc-vtl-moves-…


http://www.hotstockspoint.com/popular-mover-to-observe-vital…


http://theenterpriseleader.com/analyst-research/price-target…


http://www.automobile-recalls.net/upsurging-stock-gaining-pr…

http://www.engelwooddaily.com/volume-spiking-and-volatility-…

https://www.equities.com/news/vital-therapies-inc-vtl-jumps-…


Vital Therapies Inc. (VTL) was among the biggest gainers on the Russell 2000 for Wednesday November 09 as the stock popped 9.65% to $6.25, representing a gain of $0.55 per share. Some 249,659 shares traded hands on 4,615 trades, compared with an average daily volume of 47,380 shares out of a total float of 32.05 million. The stock opened at $5.80 and traded with an intraday range of $6.50 to $5.58.

After today's gains, Vital Therapies Inc. reached a market cap of $200.32 million. Vital Therapies Inc. has had a trading range between $11.80 and $5.00 over the last year, and it had a 50-day SMA of $5.91 and a 200-day SMA of $7.33.

Vital Therapies Inc is a biotherapeutic company. The Company is engaged in developing a cell-based therapy targeting treatment acute forms of liver failure. Its product includes the ELAD System an extracorporeal bio-artificial liver support system.

Vital Therapies Inc. is based out of San Diego, CA and has some 78 employees. Its CEO is Terence E. Winters.

For a complete fundamental analysis analysis of Vital Therapies Inc., check out Equities.com’s Stock Valuation Analysis report for VTL. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.


http://newsden.net/analysts-price-targets/analyst-review-vit…

[GooGel]

VTL !!!!!!!!!!!!!!!!!! 6 ziel 30 wird kommen

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=VTL&uf=8&type=4&size=4&sid=13758312&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=1256735223&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

EYEGW Eyegate Pharmaceuticals Inc. Wt 0.48 +0.28 140.00% 24,600 11,808
PTCT PTC Therapeutics Inc. 11.30 +5.30 88.33% 21,534,851 243.34M
CLRBW Cellectar Biosciences Inc. Wt 0.29 +0.08 38.10% 2,567 744
HEAR Turtle Beach Corp. 1.94 +0.52 36.62% 2,633,692 5.11M
FATE Fate Therapeutics Inc. 2.93 +0.78 36.28% 403,813 1.18M
CGNT Cogentix Medical Inc. 2.22 +0.56 33.73% 373,441 829,039
NVDA NVIDIA Corp. 87.97 +20.20 29.81% 54,142,206 4.76B
DMTX Dimension Therapeutics Inc. 5.75 +1.20 26.37% 161,463 928,412
SINO Sino-Global Shipping America Ltd. 1.4622 +0.3023 26.06% 3,164,183 4.63M
CXRX Concordia International Corp. 2.83 +0.58 25.78% 7,002,005 19.82M
VTL Vital Therapies Inc. 6.15 +1.15 23.00% 140,940 866,781
STRS Stratus Properties Inc. 31.35 +5.80 22.70% 33,680 1.06M
HIIQ Health Insurance Innovations Inc. Cl A 9.20 +1.70 22.67% 1,147,794 10.56M
EDGE Edge Therapeutics Inc. 12.25 +2.24 22.38% 184,813 2.26M
AGFS AgroFresh Solutions Inc. 2.47 +0.45 22.28% 907,423 2.24M
SAUC Diversified Restaurant Holdings Inc. 1.01 +0.18 21.69% 309,264 312,357
CYHHZ Community Health Systems Inc. Rt 0.0097 +0.0017 21.25% 761,000 7,382
RXDX Ignyta Inc. 6.65 +1.15 20.91% 359,221 2.39M
CPAAW Conyers Park Acquisition Corp. Wt 4.23 +0.73 20.86% 100 423
CRDS Crossroads Systems Inc. 4.34 +0.74 20.56% 94,142 408,576
SMSI Smith Micro Software Inc. 1.78 +0.3021 20.44% 122,554 218,146
EGLE Eagle Bulk Shipping Inc. 6.08 +1.02 20.16% 2,223,529 13.52M
BSQR BSQUARE Corp. 4.60 +0.75 19.48% 153,165 704,559
ROIA Radio One Inc. Cl A 3.00 +0.474 18.76% 7,734 23,202
FNCX Function(x) Inc. 3.5063 +0.5511 18.65% 72,328 253,604

[GooGel]

Überblick!!!!!!!!!!1 geringe Umsätze!!!!!!!!!!!!!!!

EYEGW Eyegate Pharmaceuticals Inc. Wt 0.48 +0.28 140.00% 24,600 11,808
PTCT PTC Therapeutics Inc. 11.30 +5.30 88.33% 21,534,851 243.34M
CLRBW Cellectar Biosciences Inc. Wt 0.29 +0.08 38.10% 2,567 744
HEAR Turtle Beach Corp. 1.94 +0.52 36.62% 2,633,692 5.11M
FATE Fate Therapeutics Inc. 2.93 +0.78 36.28% 403,813 1.18M
CGNT Cogentix Medical Inc. 2.22 +0.56 33.73% 373,441 829,039
NVDA NVIDIA Corp. 87.97 +20.20 29.81% 54,142,206 4.76B
DMTX Dimension Therapeutics Inc. 5.75 +1.20 26.37% 161,463 928,412
SINO Sino-Global Shipping America Ltd. 1.4622 +0.3023 26.06% 3,164,183 4.63M
CXRX Concordia International Corp. 2.83 +0.58 25.78% 7,002,005 19.82M
VTL Vital Therapies Inc. 6.15 +1.15 23.00% 140,940 866,781
STRS Stratus Properties Inc. 31.35 +5.80 22.70% 33,680 1.06M
HIIQ Health Insurance Innovations Inc. Cl A 9.20 +1.70 22.67% 1,147,794 10.56M
EDGE Edge Therapeutics Inc. 12.25 +2.24 22.38% 184,813 2.26M
AGFS AgroFresh Solutions Inc. 2.47 +0.45 22.28% 907,423 2.24M
SAUC Diversified Restaurant Holdings Inc. 1.01 +0.18 21.69% 309,264 312,357
CYHHZ Community Health Systems Inc. Rt 0.0097 +0.0017 21.25% 761,000 7,382
RXDX Ignyta Inc. 6.65 +1.15 20.91% 359,221 2.39M
CPAAW Conyers Park Acquisition Corp. Wt 4.23 +0.73 20.86% 100 423
CRDS Crossroads Systems Inc. 4.34 +0.74 20.56% 94,142 408,576
SMSI Smith Micro Software Inc. 1.78 +0.3021 20.44% 122,554 218,146
EGLE Eagle Bulk Shipping Inc. 6.08 +1.02 20.16% 2,223,529 13.52M
BSQR BSQUARE Corp. 4.60 +0.75 19.48% 153,165 704,559
ROIA Radio One Inc. Cl A 3.00 +0.474 18.76% 7,734 23,202
FNCX Function(x) Inc. 3.5063 +0.5511 18.65% 72,328 253,604

[GooGel]

EYEGW---Eyegate Pharmaceuticals Inc. W----SPAZ hoch 7!!!!!!!!!!!!0,05 Ziel 5!!!!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=EYEGW&uf=8&type=4&size=4&sid=20214488&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1179309970&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

http://www.eyegatepharma.com/


die analysten werden wach



http://www.duncanindependent.com/penny-stock-news-looking-closer-at-eyegate-pharmaceuticals-inc-nasdaqeyeg/39579/

http://www.com-unik.info/2016/11/12/zacks-investment-researc…


Zacks Investment Research Comments on Eyegate Pharmaceuticals Inc’s FY2016 Earnings (EYEG)
Posted by Eileen French on Nov 12th, 2016 // No Comments
Eyegate Pharmaceuticals logoEyegate Pharmaceuticals Inc (NASDAQ:EYEG) – Investment analysts at Zacks Investment Research lifted their FY2016 earnings per share (EPS) estimates for Eyegate Pharmaceuticals in a research report issued on Tuesday. Zacks Investment Research analyst B. Marckx now anticipates that the firm will post earnings per share of ($1.55) for the year, up from their prior forecast of ($1.64). Zacks Investment Research also issued estimates for Eyegate Pharmaceuticals’ FY2017 earnings at ($0.83) EPS, FY2018 earnings at ($0.67) EPS and FY2019 earnings at ($0.77) EPS.
Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Eyegate Pharmaceuticals in a research report on Tuesday, October 25th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $9.20.
Shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) opened at 1.43 on Friday. The firm’s market capitalization is $12.80 million. The company’s 50-day moving average is $1.57 and its 200 day moving average is $2.30. Eyegate Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $5.10.
An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC purchased a new position in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 386,940 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,002,000. Sabby Management LLC owned approximately 4.64% of Eyegate Pharmaceuticals as of its most recent filing with the SEC.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
5 Day Chart for NASDAQ:EYEG
What are top analysts saying about Eyegate Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eyegate Pharmaceuticals Inc and related companies.

[GooGel]

Eyegate Pharmaceuticals Inc!!!!!!!!!!! Wo handeln?

http://www.duncanindependent.com/penny-stock-news-looking-cl…

Zacks Investment Research Comments on Eyegate Pharmaceuticals Inc’s FY2016 Earnings (EYEG)
Posted by Eileen French on Nov 12th, 2016 // No Comments
Eyegate Pharmaceuticals logoEyegate Pharmaceuticals Inc (NASDAQ:EYEG) – Investment analysts at Zacks Investment Research lifted their FY2016 earnings per share (EPS) estimates for Eyegate Pharmaceuticals in a research report issued on Tuesday. Zacks Investment Research analyst B. Marckx now anticipates that the firm will post earnings per share of ($1.55) for the year, up from their prior forecast of ($1.64). Zacks Investment Research also issued estimates for Eyegate Pharmaceuticals’ FY2017 earnings at ($0.83) EPS, FY2018 earnings at ($0.67) EPS and FY2019 earnings at ($0.77) EPS.
Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Eyegate Pharmaceuticals in a research report on Tuesday, October 25th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $9.20.
Shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) opened at 1.43 on Friday. The firm’s market capitalization is $12.80 million. The company’s 50-day moving average is $1.57 and its 200 day moving average is $2.30. Eyegate Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $5.10.
An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC purchased a new position in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 386,940 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,002,000. Sabby Management LLC owned approximately 4.64% of Eyegate Pharmaceuticals as of its most recent filing with the SEC.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
5 Day Chart for NASDAQ:EYEG


http://www.com-unik.info/2016/11/12/zacks-investment-researc…

https://www.marketbeat.com/stocks/NASDAQ/EYEG/

https://www.marketbeat.com/stocks/NASDAQ/EYEG/

EYEG STOCK CHART
EYEGATE PHARMACEUTICALS INC
1.430.05 (3.62%) !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

0,5 ??????????????

[GooGel]

EYEG Eyegate Pharmaceuticals Inc. (NASDAQ)!!!!!!!!!!!!!SAMSTAG mit Bericht!!!!!!!!!! 1,5 Ziel 36

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=EYEG&uf=8&type=4&size=4&sid=16135206&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=1421426487&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=EYEG&uf=8&type=4&size=4&sid=16135206&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=1421426487&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=EYEG&uf=8&type=4&size=4&sid=16135206&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=1421426487&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
Published: Nov 2, 2016 9:20 a.m. ET


WALTHAM, Mass., Nov 02, 2016 (GLOBE NEWSWIRE via COMTEX) --

EyeGate Pharmaceuticals, Inc. EYEG, +3.62% ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced financial results for the three-month period ended September 30, 2016, and provided an update on recent corporate and operational activities.
Third Quarter 2016 and Recent Business Highlights:

Reported positive top-line data from Phase 1b/2a clinical trial of the EGP-437 combination product for treatment of post-operative inflammation and pain in cataract surgery patients;
Received additional milestone payment from Valeant Pharmaceuticals International, Inc. ("Valeant") for EGP-437 in uveitis;
Continued enrolling patients in confirmatory Phase 3 clinical trial of the EGP-437 combination product targeting non-infectious anterior uveitis;
Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense to continue development of cross-linked thiolated hyaluronic acid ("CMHA-S") for use as an ocular bandage film;
"We made continued, significant progress in the third quarter as we further advanced both the EGP-437 combination product and the EyeGate OBG programs, and positioned the Company to achieve key milestones over the next 12 months," said Stephen From, President and Chief Executive Officer of EyeGate. "The three new cohorts in our Phase 1b/2a trial of the EGP-437 combination product in cataract surgery patients have progressed according to plan and we remain on track to report top-line data from these cohorts in the fourth quarter of 2016. We believe that these additional cohorts, which are evaluating additional doses and dosing regimens of EGP-437, will allow us to build upon the positive top-line data we reported in August and to initiate a randomized, placebo-controlled trial of EGP-437 in cataract surgery patients in the first quarter of 2017.

"In addition, patient enrollment in the confirmatory Phase 3 trial of the EGP-437 combination product in uveitis progressed, and the Company earned another milestone payment under our worldwide licensing agreement with Valeant for this indication. We continue to target an NDA submission for the EGP-437 combination product in uveitis in late 2017."

Mr. From continued, "We are extremely pleased with the progress we have made on the EGP-437 combination product, and have also taken important steps forward in the development of our CHMA-S platform and its lead product, the EyeGate OBG. We are on track for a meeting with the FDA and expect to initiate our first CMHA-S clinical trial, in corneal repair, by the end of the year. Additionally, we received the second year of funding of our Phase II SBIR grant from the U.S. Department of Defense to continue studying the use of CMHA-S as an ocular bandage film, which represents a large potential market. We are extremely excited about what the future holds for EyeGate and look forward to the opportunities that lie ahead."

Third Quarter 2016 Financial Review

EyeGate's revenue for the third quarter of 2016 totaled $0.274 million, compared with no revenue in the third quarter of 2015. Third quarter 2016 revenue was attributable to U.S. government grants to fund the Company's CMHA-S product. Net loss for the quarter was $(3.377) million, compared with $(1.356) million in the third quarter of 2015. The increase in net loss was attributable to expenses relating to the Company's confirmatory Phase 3 trial of EGP-437 in anterior uveitis, its Phase 1b/2a trial for post-cataract surgery inflammation and pain and the continued development of the EyeGate OBG, as well as increased R&D, general and administrative and other expenses in support of these activities.

Research and Development Expenses. Research and development expenses were $2.449 million for the three months ended September 30, 2016, compared to $0.408 million for the three months ended September 30, 2015. The increase of $2.041 million is primarily due to an increase in clinical and other activity related to the acceleration of Phase 3 clinical trials for the treatment of anterior uveitis, the Phase 1b/2a trial for post-cataract surgery inflammation and pain, and the development of and clinical trial for the EyeGate OBG, as well as research expenses attributable to the Company's EGP-437-based and CMHA-S-based product pipelines.

General and Administrative Expenses. General and administrative expenses were $1.202 million for the three months ended September 30, 2016, compared to $0.946 million for the three months ended September 30, 2015. The increase of $0.256 million was due primarily to increases in payroll, office and other expenses as company operations have expanded with the acceleration in clinical activity related to the EGP-437 Phase 3 trials for the treatment of anterior uveitis, the Phase 1b/2a trial for post-cataract surgery inflammation and pain, and the clinical trial for the EyeGate OBG, as well as the expansion of operations following the Jade Acquisition.

About EyeGate:

EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. The EGP-437 combination product, EyeGate's first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate's proprietary innovative drug delivery system, the EyeGate(R) II Delivery System. In addition, EyeGate is developing, through its wholly-owned Jade subsidiary, products using cross-linked thiolated carboxymethyl hyaluronic acid ("CMHA-S"), a modified form of the natural polymer hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. EyeGate intends to initiate a clinical study for Jade's lead product candidate for corneal epithelial defects by year-end 2016. For more information, please visit www.EyeGatePharma.com.

[GooGel]

EYEG 1,5----------Ziel 10 bis 35

Zacks Investment Research Comments on Eyegate Pharmaceuticals Inc’s FY2016 Earnings (EYEG)
Posted by Eileen French on Nov 12th, 2016 // No Comments
Eyegate Pharmaceuticals logoEyegate Pharmaceuticals Inc (NASDAQ:EYEG) – Investment analysts at Zacks Investment Research lifted their FY2016 earnings per share (EPS) estimates for Eyegate Pharmaceuticals in a research report issued on Tuesday. Zacks Investment Research analyst B. Marckx now anticipates that the firm will post earnings per share of ($1.55) for the year, up from their prior forecast of ($1.64). Zacks Investment Research also issued estimates for Eyegate Pharmaceuticals’ FY2017 earnings at ($0.83) EPS, FY2018 earnings at ($0.67) EPS and FY2019 earnings at ($0.77) EPS.
Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Eyegate Pharmaceuticals in a research report on Tuesday, October 25th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $9.20.
Shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) opened at 1.43 on Friday. The firm’s market capitalization is $12.80 million. The company’s 50-day moving average is $1.57 and its 200 day moving average is $2.30. Eyegate Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $5.10.
An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC purchased a new position in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 386,940 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,002,000. Sabby Management LLC owned approximately 4.64% of Eyegate Pharmaceuticals as of its most recent filing with the SEC.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.



Zacks Investment Research Kommentare zu EyeGate Pharmaceuticals Inc FY2016 Ergebnis (EYEG)
Geschrieben von Eileen Französisch am 12. November 2016 // Keine Kommentare
EyeGate Pharmaceuticals logoEyeGate Pharmaceuticals Inc (NASDAQ: EYEG) - Investition Analysten von Zacks Investment Research hob ihre FY2016 das Ergebnis je Aktie (EPS) die Schätzungen für EyeGate Pharmaceuticals in einem Forschungsbericht am Dienstag ausgegeben. Zacks Investment Research Analyst B. Marckx erwartet nun, dass das Unternehmen das Ergebnis je Aktie von (1,55 $) für das Jahr veröffentlichen wird, im Vergleich zu ihrer vorherigen Prognose von ($ 1,64). Zacks Investment Research ausgegeben Schätzungen für FY2017 Ergebnis 'EyeGate Pharmaceuticals auch bei ($ 0,83) EPS, FY2018 Ergebnis bei ($ 0,67) EPS und FY2019 Ergebnis bei ($ 0,77) EPS.
Getrennt davon wurden neu aufgelegt HC Wainwright ein Rating "buy" und gab eine $ 10,00 Kursziel auf Aktien der EyeGate Pharmaceuticals in einem Forschungsbericht am Dienstag 25. Oktober. Ein Aktienresearch-Analyst hat die Aktie mit einer Halte bewertet und fünf haben eine Kaufempfehlung an den ausgegebenen Aktien. Das Unternehmen hat eine Konsensus-Rating von "Buy" und einem Konsens Zielpreis von $ 9,20.
Die Aktien der EyeGate Pharmaceuticals ( NASDAQ: EYEG ) eröffnet am Freitag um 1.43. Die Marktkapitalisierung des Unternehmens beträgt 12,80 Mio. $. Die 50-Tage - Unternehmen gleitenden Durchschnitt ist 1,57 $ und seine 200 - Tage - Durchschnitt ist 2,30 $. EyeGate Pharmaceuticals verfügt über eine 52 - Wochentief von $ 1.11 und eine 52 - Wochenhoch von 5,10 $.
Ein institutioneller Investor kaufte vor kurzem eine neue Position in EyeGate Pharmaceuticals Aktien. Sabby Management LLC gekauft, eine neue Position in EyeGate Pharmaceuticals Inc (NASDAQ: EYEG) im zweiten Quartal, nach seinem letzten 13F Einreichung bei der Securities and Exchange Commission. Der institutionelle Anleger erworben 386.940 Aktien des Spezial Aktien des Pharmaunternehmen, bei etwa 1.002.000 $ geschätzt. Sabby Management LLC besaß etwa 4,64% von EyeGate Pharmaceuticals als seiner jüngsten Einreichung bei der SEC.
EyeGate Pharmaceuticals Company Profile
EyeGate Pharmaceuticals, Inc ist eine klinische Phase-Spezialpharma-Unternehmen. Das Unternehmen konzentriert sich auf die Entwicklung und Vermarktung Therapeutika und Drug-Delivery-Systeme für Erkrankungen des Auges zu behandeln. Die Gesellschaft führen Produkt, EGP-437, verfügt über eine neu formulierte topisch aktive Corticosteroid, Dexamethason-Phosphat, die in die Augengewebe durch seine Medikamentenabgabesystem geliefert wird, das System der EyeGate II Lieferung.

[GooGel]

Market cap $13.61M normal wäre 130M

http://www.marketwatch.com/investing/stock/EYEG

EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
Published: Nov 2, 2016 9:20 a.m. ET


WALTHAM, Mass., Nov 02, 2016 (GLOBE NEWSWIRE via COMTEX) --

EyeGate Pharmaceuticals, Inc. EYEG, +3.62% ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced financial results for the three-month period ended September 30, 2016, and provided an update on recent corporate and operational activities.
Third Quarter 2016 and Recent Business Highlights:

Reported positive top-line data from Phase 1b/2a clinical trial of the EGP-437 combination product for treatment of post-operative inflammation and pain in cataract surgery patients;
Received additional milestone payment from Valeant Pharmaceuticals International, Inc. ("Valeant") for EGP-437 in uveitis;
Continued enrolling patients in confirmatory Phase 3 clinical trial of the EGP-437 combination product targeting non-infectious anterior uveitis;
Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense to continue development of cross-linked thiolated hyaluronic acid ("CMHA-S") for use as an ocular bandage film;
"We made continued, significant progress in the third quarter as we further advanced both the EGP-437 combination product and the EyeGate OBG programs, and positioned the Company to achieve key milestones over the next 12 months," said Stephen From, President and Chief Executive Officer of EyeGate. "The three new cohorts in our Phase 1b/2a trial of the EGP-437 combination product in cataract surgery patients have progressed according to plan and we remain on track to report top-line data from these cohorts in the fourth quarter of 2016. We believe that these additional cohorts, which are evaluating additional doses and dosing regimens of EGP-437, will allow us to build upon the positive top-line data we reported in August and to initiate a randomized, placebo-controlled trial of EGP-437 in cataract surgery patients in the first quarter of 2017.

"In addition, patient enrollment in the confirmatory Phase 3 trial of the EGP-437 combination product in uveitis progressed, and the Company earned another milestone payment under our worldwide licensing agreement with Valeant for this indication. We continue to target an NDA submission for the EGP-437 combination product in uveitis in late 2017."

Mr. From continued, "We are extremely pleased with the progress we have made on the EGP-437 combination product, and have also taken important steps forward in the development of our CHMA-S platform and its lead product, the EyeGate OBG. We are on track for a meeting with the FDA and expect to initiate our first CMHA-S clinical trial, in corneal repair, by the end of the year. Additionally, we received the second year of funding of our Phase II SBIR grant from the U.S. Department of Defense to continue studying the use of CMHA-S as an ocular bandage film, which represents a large potential market. We are extremely excited about what the future holds for EyeGate and look forward to the opportunities that lie ahead."

Third Quarter 2016 Financial Review

EyeGate's revenue for the third quarter of 2016 totaled $0.274 million, compared with no revenue in the third quarter of 2015. Third quarter 2016 revenue was attributable to U.S. government grants to fund the Company's CMHA-S product. Net loss for the quarter was $(3.377) million, compared with $(1.356) million in the third quarter of 2015. The increase in net loss was attributable to expenses relating to the Company's confirmatory Phase 3 trial of EGP-437 in anterior uveitis, its Phase 1b/2a trial for post-cataract surgery inflammation and pain and the continued development of the EyeGate OBG, as well as increased R&D, general and administrative and other expenses in support of these activities.

Research and Development Expenses. Research and development expenses were $2.449 million for the three months ended September 30, 2016, compared to $0.408 million for the three months ended September 30, 2015. The increase of $2.041 million is primarily due to an increase in clinical and other activity related to the acceleration of Phase 3 clinical trials for the treatment of anterior uveitis, the Phase 1b/2a trial for post-cataract surgery inflammation and pain, and the development of and clinical trial for the EyeGate OBG, as well as research expenses attributable to the Company's EGP-437-based and CMHA-S-based product pipelines.

General and Administrative Expenses. General and administrative expenses were $1.202 million for the three months ended September 30, 2016, compared to $0.946 million for the three months ended September 30, 2015. The increase of $0.256 million was due primarily to increases in payroll, office and other expenses as company operations have expanded with the acceleration in clinical activity related to the EGP-437 Phase 3 trials for the treatment of anterior uveitis, the Phase 1b/2a trial for post-cataract surgery inflammation and pain, and the clinical trial for the EyeGate OBG, as well as the expansion of operations following the Jade Acquisition.

About EyeGate:

EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. The EGP-437 combination product, EyeGate's first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate's proprietary innovative drug delivery system, the EyeGate(R) II Delivery System. In addition, EyeGate is developing, through its wholly-owned Jade subsidiary, products using cross-linked thiolated carboxymethyl hyaluronic acid ("CMHA-S"), a modified form of the natural polymer hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. EyeGate intends to initiate a clinical study for Jade's lead product candidate for corneal epithelial defects by year-end 2016. For more information, please visit www.EyeGatePharma.com.

http://www.eyegatepharma.com/wp-content/uploads/2016/09/EyeG…

[GooGel]

http://www.eyegatepharma.com/investors/sec-filings/

file:///C:/Users/Frenzel/Downloads/11205972.pdf

SEC FILIING,

Also die schreiben noch Verluste aber könnten auch bald Gewinne schriebn.
Eine echte Perle

Wenn alles sauber läuft.
Man sollte mal einen Besuch abstatten.

[GooGel]

Die Firma gibt es

https://www.google.de/maps/@42.3844082,-71.208622,3a,75y,196…

[GooGel]

DULL Direxion Daily Silver Miners Index Bear 2X Shares 41.59 +12.99 45.42% 13,353 555,351
JDST Direxion Daily Junior Gold Miners Index Bear 3X Shares 40.87 +8.48 26.18% 11,841,764 483.97M
DUST Direxion Daily Gold Miners Index Bear 3x Shares 56.27 +11.41 25.43% 13,936,951 784.23M
NM Navios Maritime Holdings Inc. 1.52 +0.30 24.59% 3,405,017 5.18M
KDMN Kadmon Holdings Inc. 6.56 +1.13 20.81% 77,525 508,564
TRTN Triton International Ltd. 16.20 +2.79 20.81% 1,014,161 16.43M
CUPM iPath Pure Beta Copper ETN 27.8866 +4.0866 17.17% 512 14,278
DYN.WS Dynegy Inc. Wt 0.09 +0.0129 16.73% 15,463 1,392
AAC AAC Holdings Inc. 8.87 +1.24 16.25% 576,974 5.12M
GDXS ProShares UltraShort Gold Miners 22.99 +3.20 16.17% 96,492 2.22M
SALT Scorpio Bulkers Inc. 4.80 +0.65 15.66% 2,053,779 9.86M
NL NL Industries Inc. 5.50 +0.70 14.58% 54,691 300,801
TGH Textainer Group Holdings Ltd. 9.95 +1.20 13.71% 801,386 7.97M
TCB.WS TCF Financial Corp. Wt 1.85 +0.22 13.50% 300 555
MODN Model N Inc. 8.45 +1.00 13.42% 328,588 2.78M
DHX DHI Group Inc. 6.50 +0.75 13.04% 476,690 3.10M
ZSL ProShares UltraShort Silver 33.5431 +3.8531 12.98% 226,115 7.58M
ARC ARC Document Solutions Inc. 4.36 +0.49 12.66% 286,716 1.25M
AP Ampco-Pittsburgh Corp. 14.25 +1.55 12.20% 41,195 587,029
QHC Quorum Health Corp. 4.72 +0.50 11.85% 1,203,711 5.68M
GM.WS.B General Motors Co. Wt 2019 15.80 +1.63 11.50% 434,651 6.87M
SOXL Direxion Daily Semiconductor Bull 3X Shares 47.75 +4.84 11.28% 597,765 28.54M
HAKK Direxion Daily Cyber Security & IT Bull 2X Shares 38.2336 +3.8659 11.25% 507 19,384
LXFT Luxoft Holding Inc. 54.25 +5.40 11.05% 631,430 34.26M
ONDK On Deck Capital Inc.

[GooGel]

IMUC.WS ImmunoCellular Therapeutics Ltd. Wt 0.04 +0.015 60.00% 35,200 1,408
AWX Avalon Holdings Corp. 3.0601 +0.6602 27.51% 47,777 146,202
ESNC EnSync Inc. 0.9899 +0.2099 26.91% 1,027,127 1.02M
AST Asterias Biotherapeutics Inc. 4.40 +0.80 22.22% 539,151 2.37M
YUMA Yuma Energy Inc. 2.95 +0.48 19.43% 267,223 788,308
AXN Aoxing Pharmaceutical Co. Inc. 0.45 +0.0609 15.65% 161,871 72,842
STRP Straight Path Communications Inc. Cl B 27.00 +3.51 14.94% 178,596 4.82M
AMPE Ampio Pharmaceuticals Inc. 0.7299 +0.0919 14.40% 392,664 286,605
FPP.WS FieldPoint Petroleum Corp. Wt 0.0125 +0.0015 13.64% 3,465 43
LGL LGL Group Inc. 4.15 +0.45 12.16% 7,854 32,594
BTX.WS BioTime Inc. Wt 0.74 +0.08 12.12% 10,055 7,441
OCX OncoCyte Corp. 5.05 +0.47 10.26% 20,093 101,470
AST.WS Asterias Biotherapeutics Inc. Wt 0.45 +0.04 9.76% 30,623 13,780
VII Vicon Industries Inc. 0.56 +0.048 9.38% 73,588 41,209
UQM UQM Technologies Inc. 0.5552 +0.0472 9.29% 244,446 135,716
WYY WidePoint Corp. 0.5675 +0.0475 9.13% 477,225 270,825
DSS Document Security Systems Inc. 0.48 +0.04 9.09% 33,540 16,099
LTS Ladenburg Thalmann Financial Services Inc. 2.41 +0.20 9.05% 479,017 1.15M
DLA Delta Apparel Co. 18.80 +1.55 8.99% 59,689 1.12M
EVI EnviroStar Inc. 11.00 +0.90 8.91% 17,072 187,792
TRXC TransEnterix Inc. 1.63 +0.13 8.67% 813,632 1.33M
CVM.WS CEL-SCI Corp. Wt 0.11 +0.0087 8.59% 15,186 1,670
PLM Polymet Mining Corp. 0.8577 +0.0677 8.57% 374,872 321,528
EPM Evolution Petroleum Corp. 8.40 +0.65 8.39% 302,928 2.54M
HCHC HC2 Holdings Inc. 4.54 +0.35 8.35% 581,483 2.64M

[GooGel]

EYEGW Eyegate Pharmaceuticals Inc. Wt 0.48 +0.28 140.00% 24,600 11,808 PTCT PTC Therapeutics Inc. 11.30 +5.30 88.33% 21,534,851 243.34M CLRBW Cellectar Biosciences Inc. Wt 0.29 +0.08 38.10% 2,567 744 HEAR Turtle Beach Corp. 1.94 +0.52 36.62% 2,633,692 5.11M FATE Fate Therapeutics Inc. 2.93 +0.78 36.28% 403,813 1.18M CGNT Cogentix Medical Inc. 2.22 +0.56 33.73% 373,441 829,039 NVDA NVIDIA Corp. 87.97 +20.20 29.81% 54,142,206 4.76B DMTX Dimension Therapeutics Inc. 5.75 +1.20 26.37% 161,463 928,412 SINO Sino-Global Shipping America Ltd. 1.4622 +0.3023 26.06% 3,164,183 4.63M CXRX Concordia International Corp. 2.83 +0.58 25.78% 7,002,005 19.82M VTL Vital Therapies Inc. 6.15 +1.15 23.00% 140,940 866,781 STRS Stratus Properties Inc. 31.35 +5.80 22.70% 33,680 1.06M HIIQ Health Insurance Innovations Inc. Cl A 9.20 +1.70 22.67% 1,147,794 10.56M EDGE Edge Therapeutics Inc. 12.25 +2.24 22.38% 184,813 2.26M AGFS AgroFresh Solutions Inc. 2.47 +0.45 22.28% 907,423 2.24M SAUC Diversified Restaurant Holdings Inc. 1.01 +0.18 21.69% 309,264 312,357 CYHHZ Community Health Systems Inc. Rt 0.0097 +0.0017 21.25% 761,000 7,382 RXDX Ignyta Inc. 6.65 +1.15 20.91% 359,221 2.39M CPAAW Conyers Park Acquisition Corp. Wt 4.23 +0.73 20.86% 100 423 CRDS Crossroads Systems Inc. 4.34 +0.74 20.56% 94,142 408,576 SMSI Smith Micro Software Inc. 1.78 +0.3021 20.44% 122,554 218,146 EGLE Eagle Bulk Shipping Inc. 6.08 +1.02 20.16% 2,223,529 13.52M BSQR BSQUARE Corp. 4.60 +0.75 19.48% 153,165 704,559 ROIA Radio One Inc. Cl A 3.00 +0.474 18.76% 7,734 23,202 FNCX Function(x) Inc. 3.5063 +0.5511 18.65% 72,328 253,604 ZitatAntwort 0 4

Mein Überblick Tagesgewinner | wallstreet-online.de - Vollständige Diskussion unter:
http://www.wallstreet-online.de/diskussion/1241385-21-30/ueb…

[GooGel]

EYEGW Eyegate Pharmaceuticals Inc. Wt 0.48 +0.28 140.00% 24,600 11,808
PTCT PTC Therapeutics Inc. 11.30 +5.30 88.33% 21,534,851 243.34M
CLRBW Cellectar Biosciences Inc. Wt 0.29 +0.08 38.10% 2,567 744
HEAR Turtle Beach Corp. 1.94 +0.52 36.62% 2,633,692 5.11M
FATE Fate Therapeutics Inc. 2.93 +0.78 36.28% 403,813 1.18M
CGNT Cogentix Medical Inc. 2.22 +0.56 33.73% 373,441 829,039
NVDA NVIDIA Corp. 87.97 +20.20 29.81% 54,142,206 4.76B
DMTX Dimension Therapeutics Inc. 5.75 +1.20 26.37% 161,463 928,412
SINO Sino-Global Shipping America Ltd. 1.4622 +0.3023 26.06% 3,164,183 4.63M
CXRX Concordia International Corp. 2.83 +0.58 25.78% 7,002,005 19.82M
VTL Vital Therapies Inc. 6.15 +1.15 23.00% 140,940 866,781
STRS Stratus Properties Inc. 31.35 +5.80 22.70% 33,680 1.06M
HIIQ Health Insurance Innovations Inc. Cl A 9.20 +1.70 22.67% 1,147,794 10.56M
EDGE Edge Therapeutics Inc. 12.25 +2.24 22.38% 184,813 2.26M
AGFS AgroFresh Solutions Inc. 2.47 +0.45 22.28% 907,423 2.24M
SAUC Diversified Restaurant Holdings Inc. 1.01 +0.18 21.69% 309,264 312,357
CYHHZ Community Health Systems Inc. Rt 0.0097 +0.0017 21.25% 761,000 7,382
RXDX Ignyta Inc. 6.65 +1.15 20.91% 359,221 2.39M
CPAAW Conyers Park Acquisition Corp. Wt 4.23 +0.73 20.86% 100 423
CRDS Crossroads Systems Inc. 4.34 +0.74 20.56% 94,142 408,576
SMSI Smith Micro Software Inc. 1.78 +0.3021 20.44% 122,554 218,146
EGLE Eagle Bulk Shipping Inc. 6.08 +1.02 20.16% 2,223,529 13.52M
BSQR BSQUARE Corp. 4.60 +0.75 19.48% 153,165 704,559
ROIA Radio One Inc. Cl A 3.00 +0.474 18.76% 7,734 23,202
FNCX Function(x) Inc. 3.5063 +0.5511 18.65% 72,328 253,604

[GooGel]

PTCT PTC Therapeutics Inc

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=PTCT&uf=8&type=4&size=4&sid=12636551&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1998423900&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

CLRB Cellectar Biosciences

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=CLRB&uf=8&type=4&size=4&sid=6776611&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1253679845&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Cellectar Biosciences Inc (CLRB) Is Oversold And Ready To Bounce ...
Insider Monkey (blog)-11.11.2016
Cellectar Biosciences Inc (NASDAQ:CLRB) is an oncology-focused company based in Madison, Wisconsin. Since the beginning of the year, ...
UPDATE -- Cellectar Biosciences Announces Recent Key ...
Nasdaq-11.11.2016
Alle ansehen
Nachrichtenbild für "Cellectar Biosciences Inc." von Seeking Alpha
Cellectar Biosciences Readies New Offering As Trials Advance
Seeking Alpha-10.11.2016
Cellectar Biosciences aims to raise $10 million to further develop its pipeline of phospholipid drug conjugates. The company will formally ...
0 Impact Score For Cellectar Biosciences, Inc. (NASDAQ:CLRB)
Markets Daily-11.11.2016
Today, a 0.393 daily sentiment score has been given to Cellectar Biosciences, Inc. (NASDAQ:CLRB) for articles scanned across the internet.
Forging Higher Over Past 6-Months, Can It Continue For Cellectar ...
CSZ News-vor 13 Stunden
Investors Cellectar Biosciences, Inc. (NASDAQ:CLRB) are heading into the 3rd quarter of this year on a positive note as the stock provided ...

[GooGel]

HEAR Turtle Beach Corp.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!KUV 0,3!!!!!!!!!!!Ziel 12 aktuell 1,81

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=HEAR&uf=8&type=4&size=4&sid=5516787&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=10&rand=304680370&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=HEAR&uf=8&type=4&size=4&sid=5516787&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=10&rand=304680370&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

FATE Fate Therapeutics !!!!!!!!!!!!!!!!!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=FATE&uf=8&type=4&size=4&sid=13198445&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=400382324&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

CGNTCogentix Medical Inc.!!!!!!!!! Infos sammeln!!!!!!!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=CGNT&uf=8&type=4&size=4&sid=9646&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=1817439498&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Nov 03, 2016, 16:05 ET
SHARE THIS ARTICLE

MINNEAPOLIS, Nov. 3, 2016 /PRNewswire/ -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company that develops, manufactures and markets innovative proprietary products for the urology market, today announced that its shareholders have voted at the special meeting held today to approve the previously announced $25 million securities purchase agreement with Accelmed Growth Partners, L.P. and transactions converting the debt and accrued interest owed to one of the Company's directors into common stock of the Company. Over 97% of the shares voting at the meeting voted in favor of the proposals.

"We are pleased shareholders have approved these transactions, which dramatically improve our balance sheet flexibility and resources," said Darin Hammers, President and CEO of Cogentix Medical. "The additional cash resources will allow us to more vigorously pursue urology focused business development activities with the goal of enhancing value for our physician customers and shareholders."

Cogentix Medical shareholders voted to approve two proposals at the special meeting today: i) the issuance of 16.1 million shares of Cogentix Medical common stock to Accelmed Growth Partners, L.P. in exchange for $25 million; and ii) the exchange of all the outstanding debt and accrued interest ($29.5 million in total) owed to Lewis C. Pell, one of the Company's Class I directors, for 17.7 million shares of Cogentix Medical common stock, and the cancellation of all outstanding warrants owned by Mr. Pell. The Company now has approximately $28 million in cash on hand, no debt outstanding and 60.4 million common shares outstanding with the closing of these transactions that occurred earlier today.

About Cogentix Medical

Cogentix Medical, Inc., headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom, is a global medical device company. We design, develop, manufacture and market products for flexible endoscopy with our unique product lines featuring a streamlined visualization system and proprietary sterile disposable microbial barrier, known as EndoSheath technology, providing users with efficient and cost effective endoscope turnover while enhancing patient safety. We also commercialize the Urgent® PC Neuromodulation System, an FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults. The symptoms include urinary urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on Cogentix Medical and our products, please visit us at www.cogentixmedical.com.

[GooGel]

DMTX Dimension Therapeutics Inc.!NEUE BIOFIRMA!!!!!!!!!!!!!!!! ist 5 soll 12 bis 20 163% steigen CHART!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=dmtx&uf=8&type=4&size=4&sid=20539554&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=754577278&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Dimension Therapeutics Inc. (DMTX) Coverage Initiated at Jefferies ...
Community Financial News-11.11.2016
Dimension Therapeutics logo Equities research analysts at Jefferies Group started coverage on shares of Dimension Therapeutics Inc.
Dimension Therapeutics reports 3Q loss
Yahoo Sports-11.11.2016
Jefferies Initiates a Buy Rating on Dimension Therapeutics Inc
Analyst Ratings-11.11.2016
Today's Analyst Coverage: Dimension Therapeutics, Inc. (NASDAQ ...
Benchmark Monitor-vor 12 Stunden
New Analyst Ratings On Dimension Therapeutics, Inc. (NASDAQ ...
NewsDen-vor 18 Stunden
Alle ansehen
A New Kind of Stock Chart: Dimension Therapeutics Inc (NASDAQ ...
CML News-11.11.2016
This is a real time view of the critical technical pivot points for Dimension Therapeutics Inc (NASDAQMTX) . The technical pivot points we look ...

Dimension Therapeutics Inc. (DMTX) Coverage Initiated at Jefferies Group
Posted by Carolyn Dwyer on Nov 11th, 2016 // No Comments
Dimension Therapeutics logoEquities research analysts at Jefferies Group started coverage on shares of Dimension Therapeutics Inc. (NASDAQMTX) in a note issued to investors on Friday. The brokerage set a “buy” rating and a $12.00 price target on the stock. Jefferies Group’s price objective suggests a potential upside of 163.74% from the stock’s current price.
DMTX has been the topic of a number of other reports. Zacks Investment Research raised shares of Dimension Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 25th. Canaccord Genuity set a $20.00 price target on shares of Dimension Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 11th. Finally, Chardan Capital set a $10.00 price target on shares of Dimension Therapeutics and gave the stock a “hold” rating in a research report on Sunday, August 21st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Dimension Therapeutics has a consensus rating of “Buy” and an average price target of $15.21.
Analyst Recommendations for Dimension Therapeutics (NASDAQMTX)
Dimension Therapeutics (NASDAQMTX) opened at 4.55 on Friday. The firm’s market capitalization is $113.88 million. Dimension Therapeutics has a 52-week low of $4.00 and a 52-week high of $15.55. The firm’s 50-day moving average is $6.61 and its 200 day moving average is $7.13.
Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in Dimension Therapeutics by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 239,000 shares of the company’s stock valued at $1,871,000 after buying an additional 80,200 shares in the last quarter. California State Teachers Retirement System boosted its stake in Dimension Therapeutics by 113.2% in the second quarter. California State Teachers Retirement System now owns 25,634 shares of the company’s stock valued at $154,000 after buying an additional 13,610 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Dimension Therapeutics by 180.8% in the second quarter. Bank of New York Mellon Corp now owns 28,743 shares of the company’s stock valued at $173,000 after buying an additional 18,506 shares in the last quarter. Bridgeway Capital Management Inc. bought a new stake in Dimension Therapeutics during the second quarter valued at approximately $128,000. Finally, State Street Corp boosted its stake in Dimension Therapeutics by 69.0% in the second quarter. State Street Corp now owns 110,725 shares of the company’s stock valued at $665,000 after buying an additional 45,200 shares in the last quarter. 85.80% of the stock is currently owned by institutional investors.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

[GooGel]

SINO Sino-Global Shipping America Ltd. !!!!!!!!!!!!!!! 1,4 Ziel 8!!!!!!!!!!!!!!!!!!!!!!!!!!!

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=sino&uf=8&type=4&size=4&sid=3218380&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=82014325&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

CXRX Concordia International Corp.!!!!BIO AKTIE!!!!!!! SHORTSQUEZZE!!!!!!!KANDIDAT!!! 2,8 Ziel 16 -35-45--80

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=cxrx&uf=8&type=4&size=4&sid=14026218&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=2043416018&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=cxrx&uf=8&type=4&size=4&sid=14026218&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=2043416018&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Suchergebnisse
Nachrichtenbild für "Concordia International Corp." von The Independent Republic
The Independent Republic
Concordia International Corp. (CXR:CA) Rises 25.66% for ...
Equities.com-11.11.2016
November 11 was a positive day for Concordia International Corp. (CXR:CA) as its stock finished the day having gained 25.66% to hit a price of ...
Prominent Runners: Concordia International Corp. (NASDAQ:CXRX ...
The Newburgh Press-11.11.2016
Top Biotechnology Stock Picking: Concordia International Corp ...
The Independent Republic-11.11.2016
Noticeable Stock: Concordia International Corp (NASDAQ:CXRX)
Post Registrar-11.11.2016
Brokers Ratings on: Concordia International Corp. (NASDAQ:CXRX)
FactsReporter-11.11.2016

[GooGel]

VTL Vital Therapies Inc. !!! BIO--SHORTSQUEZZE::: 6--Ziel 12-18-28 kleine Umsätze

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=vtl&uf=8&type=4&size=4&sid=13758312&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=494934962&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=vtl&uf=8&type=4&size=4&sid=13758312&style=370&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=9&rand=494934962&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

Vital Therapies Inc. (VTL) Moves Higher on Volume Spike for ...
Equities.com-11.11.2016
Vital Therapies Inc. (VTL) traded on unusually high volume on Nov. 11, as the stock gained 23% to close at $6.15. On the day, Vital Therapies ...
Breaking: Will Vital Therapies Inc Short Squeeze Soon?
Frisco Fastball-10.11.2016
Upsurging Stock Gaining Pre-Bell: Vital Therapies, Inc. (NASDAQ:VTL)
AR News-11.11.2016
Popular Mover to Observe- Vital Therapies, Inc. (NASDAQ:VTL)
Hot Stocks Point-11.11.2016
Price Target Of Vital Therapies, Inc. (NASDAQ:VTL) Stock At $8.5
Enterprise Leader-11.11.2016
Alle ansehen
Vital Therapies Inc. (VTL) Jumps 9.65% on November 09
Equities.com-09.11.2016
Vital Therapies Inc. (VTL) was among the biggest gainers on the Russell 2000 for Wednesday November 09 as the stock popped 9.65% to ...
Analyst Review: Vital Therapies, Inc. (NASDAQ:VTL)
NewsDen-09.11.2016
Alle ansehen
Earnings Focus: A Look at Vital Therapies, Inc. (NASDAQ:VTL) and ...
Consumer Eagle-vor 9 Stunden
Analysts are predicting that Vital Therapies, Inc. (NASDAQ:VTL) is going to report an earnings of $-0.33 per share. The actual earnings for Vital .


http://www.consumereagle.com/earnings-focus-a-look-at-vital-…

Breaking: Will Vital Therapies Inc Short Squeeze Soon?Nov 10, 2016, 20:15 Pm046
Breaking: Will Vital Therapies Inc Short Squeeze Soon?
The stock of Vital Therapies Inc (NASDAQ:VTL) is a huge mover today! About 150,743 shares traded hands or 206.87% up from the average. Vital Therapies Inc (NASDAQ:VTL) has declined 29.14% since April 8, 2016 and is downtrending. It has underperformed by 34.79% the S&P500.
The move comes after 7 months negative chart setup for the $188.02M company. It was reported on Nov, 10 by Barchart.com. We have $4.76 PT which if reached, will make NASDAQ:VTL worth $20.68 million less.

Vital Therapies Inc (NASDAQ:VTL) Ratings Coverage
Out of 6 analysts covering Vital Therapies Inc (NASDAQ:VTL), 2 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 33% are positive. Vital Therapies Inc has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. BTIG Research downgraded Vital Therapies Inc (NASDAQ:VTL) on Monday, October 26 to “Neutral” rating. The stock of Vital Therapies Inc (NASDAQ:VTL) has “Buy” rating given on Monday, August 24 by Canaccord Genuity. Credit Suisse reinitiated Vital Therapies Inc (NASDAQ:VTL) on Monday, August 10 with “Outperform” rating. SunTrust downgraded the shares of VTL in a report on Monday, August 24 to “Buy” rating. On Friday, August 7 the stock rating was initiated by BTIG Research with “Buy”. Suntrust Robinson downgraded the stock to “Neutral” rating in Tuesday, September 29 report. The stock of Vital Therapies Inc (NASDAQ:VTL) earned “Neutral” rating by SunTrust on Tuesday, September 29. On Monday, August 24 the stock rating was downgraded by William Blair to “Outperform”. The firm has “Neutral” rating given on Monday, August 24 by Suntrust Robinson. The rating was downgraded by Credit Suisse on Monday, August 24 to “Neutral”.

According to Zacks Investment Research, “Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California.”

Insitutional Activity: The institutional sentiment increased to 1.58 in 2016 Q2. Its up 0.13, from 1.45 in 2016Q1. The ratio is positive, as 8 funds sold all Vital Therapies Inc shares owned while 11 reduced positions. 7 funds bought stakes while 23 increased positions. They now own 8.18 million shares or 10.33% less from 9.13 million shares in 2016Q1.
State Street Corporation has invested 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL). Parametric Assoc Ltd Liability Corp has invested 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL). Voya Investment Management Ltd Liability has 0% invested in the company for 11,533 shares. Blackrock Advsr Ltd holds 0% or 11,350 shares in its portfolio. Creative Planning holds 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL) for 633 shares. Nationwide Fund Advsr holds 0% or 14,423 shares in its portfolio. Price T Rowe Md accumulated 0% or 17,900 shares. The Arizona-based Ironwood Financial Limited has invested 0% in Vital Therapies Inc (NASDAQ:VTL). Proshare Advsr Ltd Limited Liability Company reported 26,157 shares or 0% of all its holdings. Morgan Stanley has 3,251 shares for 0% of their US portfolio. Wells Fargo And Mn has 8,021 shares for 0% of their US portfolio. Deutsche National Bank & Trust Ag owns 7,356 shares or 0% of their US portfolio. Fifth Third Commercial Bank has 0% invested in the company for 3,000 shares. Moreover, Goldman Sachs Grp Inc has 0% invested in Vital Therapies Inc (NASDAQ:VTL) for 91,375 shares. Intl holds 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL) for 13,632 shares.

[GooGel]

STRS Stratus Properties Inc-------gute Beispiel Trend LONG-----

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=strs&uf=8&type=4&size=4&sid=694840&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=897702652&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

[GooGel]

HIIQ Health Insurance Innovations Inc !!!!!!!!!!!!JUNGE FIRMA 9 ziel 16 drüber --32

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=hiiq&uf=8&type=4&size=4&sid=11912602&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=550073816&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

https://www.google.de/search?hl=de&gl=de&tbm=nws&authuser=0&…


Upsurging Stock Gaining Pre-Bell: Health Insurance Innovations, Inc ...
AR News-vor 45 Minuten
Is Health Insurance Innovations, Inc. (NASDAQ:HIIQ) ready to lock in early pre-market gains? The stock is gapping higher before the bell, ...
Stock Worth Watching: What's Next for Health Insurance Innovations ...
Frisco Fastball-11.11.2016
Running Mover to Focus- Health Insurance Innovations, Inc ...
Hot Stocks Point-11.11.2016
Latest Analyst Reports On Health Insurance Innovations, Inc.
NewsDen-vor 16 Stunden
Eye Catching Stocks: Health Insurance Innovations, Inc. (NASDAQ ...
Benchmark Monitor-vor 13 Stunden
Alle ansehen
Nachrichtenbild für "Health Insurance Innovations Inc" von Press Telegraph
Notable Mover: A Reversal for Health Insurance Innovations Inc Is ...
Press Telegraph-10.11.2016
The stock of Health Insurance Innovations Inc (NASDAQ:HIIQ) is a huge mover today! About 233,934 shares traded hands or 35.39% up from ...
Health Insurance Innovations Inc. (HIIQ) Stock Rating Upgraded by ...
The Cerbat Gem-10.11.2016
Alle ansehen
92 Impact Score For Health Insurance Innovations, Inc. (NASDAQ ...
Markets Daily-11.11.2016
Today, a 0.56 daily sentiment score has been given to Health Insurance Innovations, Inc. (NASDAQ:HIIQ) for articles scanned across the ...
Health Insurance Innovations Inc. (HIIQ) Forecasted to Earn Q4 ...
The Cerbat Gem-09.11.2016
Health Insurance Innovations Inc. (HIIQ) Forecasted to Earn Q4 2016 ... Health Insurance Innovations Inc. (NASDAQ:HIIQ) – Investment ...
Are Institutions Losing Faith in Health Insurance Innovations, Inc ...
Engelwood Daily-09.11.2016
Institutional investors have decreased the number of transactions of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) over the past quarter ...
Health Insurance Innovations, Inc. Reports Record Third Quarter ...
GlobeNewswire (press release)-02.11.2016
TAMPA, Fla., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Health Insurance Innovations, Inc. (HII) (NASDAQ:HIIQ), a leading developer, distributor, ...
Health Insurance Innovations Inc. (HIIQ) Scheduled to Post Quarterly ...
BBNS-02.11.2016
Alle ansehen
Nachrichtenbild für "Health Insurance Innovations Inc" von Marea Informative
Marea Informative
Health Insurance Innovations Inc. (HIIQ) Rating Lowered to Hold at ...
BBNS-07.11.2016
Health Insurance Innovations Inc. (HIIQ) Rating Lowered to Hold at ... Health Insurance Innovations Inc. (NASDAQ:HIIQ) was downgraded by ...
Latest Analyst Ratings For Health Insurance Innovations, Inc. (HIIQ)
The De Soto Edge-07.11.2016
Alle ansehen

[GooGel]

EDGE Edge Therapeutics Inc. !!!!!!!!!! 12 ziel 26

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=edge&uf=8&type=4&size=4&sid=20326309&style=370&freq=2&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=20&rand=1283990513&compidx=aaaaa%3a0&ma=4&maval=9&lf=65536&lf2=4&lf3=268435456&height=981&width=1045&mocktick=1

[/url]

http://www.edgetherapeutics.com/

https://www.google.de/search?hl=de&gl=de&tbm=nws&authuser=0&…

[GooGel]

DYN.WS Dynegy Inc. Wt 0.0699 +0.0099 16.50% 17,558 1,227
CBR Ciber Inc. 0.80 +0.1099 15.93% 2,026,569 1.62M
CLD Cloud Peak Energy Inc. 5.645 +0.645 12.90% 5,623,209 31.74M
C.WS.A Citigroup Inc. Wt 2019 0.0877 +0.0097 12.44% 1,327,859 116,453
UGAZ VelocityShares 3x Long Natural Gas ETN linked to the S&P GSCI Natural Gas Index Excess Return 25.19 +2.64 11.71% 5,474,328 137.90M
VLY.WS Valley National Bancorp Wt 2018 0.10 +0.01 11.11% 10,388 1,039
BAC.WS.B Bank of America Corp. Cl B Wt 0.51 +0.05 10.87% 1,042,286 531,566
TDW Tidewater Inc. 2.20 +0.21 10.55% 1,297,248 2.85M
SMLL Direxion Daily Small Cap Bull 2X Shares 36.95 +3.39 10.10% 2,300 84,985
UAN CVR Partners LP 4.994 +0.414 9.04% 328,946 1.64M
DULL Direxion Daily Silver Miners Index Bear 2X Shares 43.1097 +3.5197 8.89% 11,151 480,716
ECR Eclipse Resources Corp. 2.905 +0.235 8.80% 862,146 2.50M
ASIX AdvanSix Inc. 17.982 +1.452 8.78% 457,179 8.22M
TPB Turning Point Brands Inc. 13.56 +1.08 8.65% 51,807 702,503
OIBR.C Oi S.A. ADR New 3.58 +0.27 8.16% 19,374 69,359
BIOA BioAmber Inc. 5.48 +0.41 8.09% 356,588 1.95M
BOIL ProShares Ultra Bloomberg Natural Gas 12.3814 +0.8822 7.67% 161,763 2.00M
CRK Comstock Resources Inc. 9.00 +0.63 7.53% 437,805 3.94M
BZH Beazer Homes USA Inc. 13.33 +0.82 6.55% 858,581 11.44M
CF CF Industries Holdings Inc. 28.83 +1.74 6.42% 4,881,513 140.73M
FGP Ferrellgas Partners L.P. 7.50 +0.45 6.38% 763,754 5.73M
MTB.WS M&T Bank Corp. Wt 67.00 +4.00 6.35% 1,353 90,651
KCG KCG Holdings Inc. 14.39 +0.85 6.28% 1,108,256 15.95M
HK Halcon Resources Corp. 10.075 +0.585 6.16% 355,741 3.58M
ZTO ZTO Express (Cayman) Inc. ADR 16.20 +0.94 6.16% 3,173,355 51.41M

[GooGel]

FFHL Fuwei Films (Holdings) Co. Ltd. 0.85 +0.2441 40.29% 284,145 241,523
OXBRW Oxbridge Re Holdings Ltd. Wt 0.4596 +0.1195 35.14% 1,600 735
ARWAR Arowana Inc. Rt 0.60 +0.15 33.33% 109,298 65,579
SGNL Signal Genetics Inc. 9.41 +2.28 31.98% 832,348 7.83M
PAVMW PAVmed Inc. Wt 8.00 +1.75 28.00% 1,300 10,400
DRAM Dataram Corp. 1.1489 +0.2289 24.88% 1,316,554 1.51M
ELECW Electrum Special Acquisition Corp. Wt 0.2725 +0.0525 23.86% 450 123
TNDM Tandem Diabetes Care Inc. 2.745 +0.495 22.00% 4,070,072 11.17M
NXTDW Nxt-ID Inc. Wt 0.40 +0.068 20.48% 4,267 1,707
CBYL Carbylan Therapeutics Inc. 0.676 +0.1148 20.46% 2,732,995 1.85M
TRCH Torchlight Energy Resources Inc. 1.35 +0.22 19.47% 1,404,223 1.90M
THLD Threshold Pharmaceuticals Inc. 0.5069 +0.0809 18.99% 1,176,379 596,307
EYEG Eyegate Pharmaceuticals Inc. 1.7101 +0.2601 17.94% 3,630,229 6.21M
SYUT Synutra International Inc. 5.275 +0.775 17.22% 1,599,642 8.44M
STEM StemCells Inc. 1.30 +0.19 17.12% 3,735,101 4.86M
OCUL Ocular Therapeutix Inc. 11.29 +1.65 17.12% 2,203,770 24.88M
ALBO Albireo Pharma Inc. 25.4773 +3.5773 16.33% 56,489 1.44M
DCIX Diana Containerships Inc. 4.67 +0.62 15.31% 13,282,229 62.03M
DPRX Dipexium Pharmaceuticals Inc. 1.90 +0.25 15.15% 1,173,044 2.23M
OTIV On Track Innovations Ltd. 1.23 +0.151 13.99% 268,802 330,626
TENX Tenax Therapeutics Inc. 1.64 +0.20 13.89% 231,662 379,926
IPDN Professional Diversity Network Inc. 7.65 +0.901 13.35% 111,859 855,721
SBSA Spanish Broadcasting System Inc. Cl A 3.5564 +0.4064 12.90% 58,681 208,693
STAF Staffing 360 Solutions Inc. 1.03 +0.112 12.20% 287,316 295,935
RILY B. Riley Financial Inc. 17.05 +1.80 11.80% 13,971 238,206

[GooGel]

FPP.WS FieldPoint Petroleum Corp. Wt 0.0235 +0.0081 52.60% 87,337 2,052
DSS Document Security Systems Inc. 0.85 +0.12 16.44% 255,935 217,545
GST Gastar Exploration Inc. 1.255 +0.135 12.05% 3,128,112 3.93M
AST.WS Asterias Biotherapeutics Inc. Wt 0.71 +0.07 10.94% 36,886 26,189
NAK Northern Dynasty Minerals Ltd. 1.35 +0.13 10.66% 2,326,177 3.14M
LODE Comstock Mining Inc. 0.241 +0.023 10.55% 416,965 100,489
BDR Blonder Tongue Laboratories Inc. 0.5703 +0.0506 9.74% 226,889 129,395
UAMY United States Antimony Corp. 0.30 +0.0244 8.85% 102,891 30,867
NTIP Network-1 Technologies Inc. 2.95 +0.20 7.27% 180,055 531,162
IOT Income Opportunity Realty Investors Inc. 7.80 +0.50 6.85% 15,149 118,162
GST.PA Gastar Exploration Inc. 8.625% Cum. Pfd. Series A 15.39 +0.94 6.51% 21,057 324,067
GMO General Moly Inc. 0.273 +0.0164 6.39% 286,699 78,269
BTX.WS BioTime Inc. Wt 0.7699 +0.0458 6.33% 18,026 13,878
TMQ Trilogy Metals Inc. 0.52 +0.0275 5.58% 53,363 27,749
SKY Skyline Corp. 11.92 +0.63 5.58% 13,687 163,149
XXII 22nd Century Group Inc. 1.19 +0.06 5.31% 1,323,287 1.57M
VNRX VolitionRX Ltd. 4.30 +0.20 4.88% 42,936 184,625
MOC Command Security Corp. 2.724 +0.124 4.77% 17,125 46,649
AINC Ashford Inc. 40.70 +1.843 4.74% 543 22,100
ENSV Enservco Corp. 0.6282 +0.0282 4.70% 34,653 21,769
HLTH Nobilis Health Corp. 2.825 +0.125 4.63% 489,218 1.38M
ESTE Earthstone Energy Inc. 14.31 +0.63 4.61% 106,646 1.53M
GST.PB Gastar Exploration Ltd. 10.75% Cum. Pfd. Series B 15.89 +0.67 4.40% 4,332 68,835
EIO Eaton Vance Ohio Municipal Bond Fund 14.4208 +0.6008 4.35% 294 4,240
PIP PharmAthene Inc. 3.025 +0.125 4.31% 2,849,438 8.62M